Filing Flows › Xeris Biopharma Holdings (XERS) › Q3 2026 › vs Q3 2025
Xeris Biopharma Holdings (XERS) Q3 2026 vs Q3 2025 (year over year)
Xeris Biopharma Holdings's revenue rose $32.8M (+44%) from $74.4M in Q3 2025 to $107M in Q3 2026. The biggest changes: Product revenue, net +$32.2M (+43%); Royalty, contract and other revenue +$641K (+202%). Operating margin 15.8% against 9.0% (+6.7 pts).
Xeris Biopharma Holdings, Q3 2026: revenue $107M (+44% year over year), operating margin 15.8%, net earnings $11.3M, operating cash flow $35.5M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Operating margin | 15.8% | 9.0% | +6.7 pts |
| Net margin | 10.5% | 0.8% | +9.7 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Recorlev | $71.5M | $37.0M | $34.6M | +93% |
| Gvoke | $21.7M | $25.2M | −$3.4M | -14% |
| Keveyis | $13.0M | $11.9M | $1.1M | +9% |
| Product revenue, net | $106M | $74.1M | $32.2M | +43% |
| Royalty, contract and other revenue | $958K | $317K | $641K | +202% |
| Revenue | $107M | $74.4M | $32.8M | +44% |
| Operating profit | $16.9M | $6.7M | $10.2M | +151% |
| Costs & expenses | $90.3M | $67.6M | $22.7M | +33% |
| Pre-tax earnings | $11.3M | $621K | $10.7M | 18× |
| Other expense, net | $5.6M | $6.1M | −$481K | -8% |
| Cost of revenue | $12.4M | $11.0M | $1.4M | +13% |
| Research & development | $11.1M | $7.5M | $3.6M | +48% |
| SG&A | $64.1M | $46.5M | $17.6M | +38% |
| Other operating costs | $2.7M | $2.7M | $0 | 0% |
| Net earnings | $11.3M | $621K | $10.7M | 18× |
| Depreciation & amortization | $300K | $300K | $0 | 0% |
| Share-based compensation | $10.8M | $7.6M | $3.2M | +41% |
| Working capital & other | $13.1M | $9.9M | $3.2M | +33% |
| Operating cash flow | $35.5M | $18.4M | $17.0M | +92% |
Questions
How much did Xeris Biopharma Holdings's revenue grow year over year in Q3 2026?
Xeris Biopharma Holdings's revenue rose $32.8M (+44%) from $74.4M in Q3 2025 to $107M in Q3 2026.
What drove Xeris Biopharma Holdings's revenue change in Q3 2026?
Product revenue, net +$32.2M (+43%); Royalty, contract and other revenue +$641K (+202%).